An oral MS drug from Biogen could increase the likelihood that the maker of Tysabri, which counts Carl Icahn as an investor, is taken over. Laura Mandaro interviews RBC Capital Markets' Michael ...
Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...
Balancing risk and benefit Biogen’s recombinant humanized monoclonal antibody, natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and transendothelial migration via the ...
Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab). Tysabri’s ...
Hosted on MSN2mon
Biogen Stock Declines 21.4% in 3 Months: How to Play the StockSales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has ...
Analysts on Wall Street project that Biogen Inc. (BIIB ... suggests that 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total' will likely reach $394.22 million. The estimate indicates ...
Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback